Japan and eCTD: What We Know
Mar29

Japan and eCTD: What We Know

Japan’s Pharmaceutical and Medical Devices Agency (PMDA), one of the earliest adopters of eCTD, adheres to a number of unique business rules which create a unique implementation of the eCTD specifications. Information available on eCTD best practices is also limited for this region, primarily due to lower levels of submission activity. What do we already know about submitting eCTDs in Japan and what can we expect later this decade as they implement eCTD v4.0?

Read More
FDA to Postpone Major Electronic Initiatives
Dec10

FDA to Postpone Major Electronic Initiatives

The requirement to submit certain drug applications in electronic format is at least three years off, and the target date for the implementation of the new Module 1 has been extended yet again according to representatives of the U.S. Food & Drug Administration.

Read More
Converting a Paper IND to eCTD Format
Jan22

Converting a Paper IND to eCTD Format

Conversion of a paper IND to eCTD format can be done at any time the sponsor is ready to implement eCTD. It is important to note that once an eCTD submission has been made to an application all subsequent submissions to that application must also be in eCTD format. Typically, the first submission sent to the application as an eCTD will contain the appropriate form (1571 or 356h) and cover letter indicating that all future submissions...

Read More

Impact of the FDA’s eCTD Mandate

With the FDA Safety & Innovation Act now signed into law, life science companies will need to start thinking strategically about the impact of the FDA’s eCTD mandate and how to quickly and easily comply. Since most of the larger companies already submit electronically, the greatest impact will be to the smaller, virtual companies that do not have substantial IT infrastructure in place, and lack the overall budgetary...

Read More

Regulatory Publishing Software Q&A

During a recent webinar presentation, GlobalSubmit demonstrated how IND & Pre-IND companies use our software tools to see the same views as the FDA; build their application as the FDA sees it; cut days off the time it takes to quality check bookmarks and hyperlinks; improve communications both internally and with the Agency; improve efficiency and meet important deadlines; reduce risk of technical rejections; and more! We received...

Read More